{"name":"AriBio Co., Ltd.","slug":"aribio-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AR1001","genericName":"AR1001","slug":"ar1001","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"AR1001","genericName":"AR1001","slug":"ar1001","phase":"phase_3","mechanism":"AR1001 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOMWdGNzl2MzVxdTJGTEVGUVoyaWZjWEV6dFBjbGF4d3AyTnNPdlhDNU9TRnJ0aHJLdFk0anoyam9ZbC1QanNKOTd0cjRUNW10M2R2Zk81TXRKVncyc2RJbUx0ZkY2REJaWmEtdk81c0lCaXd2b21pWmg4OGNwbi1zY09tdjJxTVFSS2phNy13SWhRVUhTYW96NmNZU2JqLUt6Z3N0dWRFUVJLczZuaGJkbG4zZTdkQlRDR3lHV1ZGaDVGd1NMLWVhOHNtTm9uUFJzblMwMktWZ3VtRDkzRk9qQloxdkotTC01SVItOTNIS2xBVTljamNZ?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight - Barchart.com","headline":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlU3TW0tTnBzTnJXMGotTkRzNkFqS2FvclNIZGhldkhUVEJILXFVU1pKOTFjemk5WlBDTEpUQUJxUUtfTlBiREZNcHN6ZncyLXp1eXJqU1lSOW15ek51dWIyTG9mTDlCWGVIMlNCLWVaalAzbTBfVWxORk9ucERjbmVJT2xKY3k4eEowcWl4Q1BSc1NOWFdZbzFsaElZNkpBMEM1Sg?oc=5","date":"2026-01-27","type":"pipeline","source":"BioWorld News","summary":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld News","headline":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcEdjVElGQ01UMmNhSFR4MjBwMFVNZ29kMExFQWdWekRiYTdVbnZZRnM1QVBWLUdFNW5DamJ6OUszNzVTRXY3b3c3T1lpQ1hJYS1iaWhIYjFYU1h0RlNfbHg2VnBlRElnaHlTQmtoQXFGb05hRXc2TTNKSFVrNmg2clNEWUVvdW43R1Ryc1NiN0NnNWhqYlZLUl9xLXRHQ2JOWUJnVFEyZ2Z5dVU?oc=5","date":"2026-01-27","type":"pipeline","source":"BioCentury","summary":"2026 Catalysts: Psychiatry, epilepsy and neurodegeneration in focus - BioCentury","headline":"2026 Catalysts: Psychiatry, epilepsy and neurodegeneration in focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBRR2N1ajhON3hteEtPcVRLQWFiN013UzBDTm9ZaHVURnR5QmdkSWJaeVZKMjd3UVJFOVZnakd0Y09wOTYxTlUxeGdjcmhyRE9xYXJCdHhlLVVxV1dZSUwzZ1lVLWcwR0hubmE2V19R0gFyQVVfeXFMTnAyVlpXVzhmemIwNWdBdjloYVYyY1Z1anRKc20xUXdQd3JLUzc0M3Z4SG0yMWM5YXpBaEhERDBDMkMzbW9pemoxMUNPaldzMmJyZklQWFRRd2tJM2NmWWRjYTZaV3g5ZnNhNUJieFozdGJ3?oc=5","date":"2026-01-07","type":"deal","source":"koreabiomed.com","summary":"AriBio inks ₩630 bil. deal with China’s Fosun Pharma for Alzheimer’s drug in ASEAN - koreabiomed.com","headline":"AriBio inks ₩630 bil. deal with China’s Fosun Pharma for Alzheimer’s drug in ASEAN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE8xQzFxNy13c2ViSVdkdXpZa09vc1k2M0pUU0h2Q2FVZTRUZ2tiWTJLZFNqOGVqNkJLWkNwbkdJTGkxX2V1ZVJmWG81NXhsQ0VPUV9nTUxIS01CajExYWljUEUtbTNzdzJLZm1SWE44TU5QdGs5?oc=5","date":"2026-01-06","type":"deal","source":"Businesskorea","summary":"Aribio Signs 630 Billion Won Dementia Drug Licensing Deal with Fosun Pharma - Businesskorea","headline":"Aribio Signs 630 Billion Won Dementia Drug Licensing Deal with Fosun Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZUZXS0FybHRkdlRJTThQNWEzYkxSYmtDTXVXQnljY3pLUnlkYTluam9ZczJ5UG56ektHb0RLZXVuazI1RFJZQXFWeE51QUtmRy1zNks5N1lOaHQ2aC1uSUV6LThlZGlOR1VpT25KR1JqLV9OMElZT25nYjRHdjlzcm5Uei1ERlZPeVVvd1l3MW5QcFJQVHNZ?oc=5","date":"2025-06-16","type":"pipeline","source":"Grand View Research","summary":"UK Alzheimer’s Therapeutics Market | Industry Report 2030 - Grand View Research","headline":"UK Alzheimer’s Therapeutics Market | Industry Report 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiQkFVX3lxTFBvaHhLTnpzcGZhejc3STJqVzBscHRxZ0RvMFMwNFRJamt4V0Q4N1NhMVNGcS1jdENlT01jekdqNnhFZw?oc=5","date":"2025-06-10","type":"deal","source":"코메디닷컴","summary":"AriBio Signs Alzheimer’s Drug Licensing Deal Worth $600 Million with UAE Pharma Company - 코메디닷컴","headline":"AriBio Signs Alzheimer’s Drug Licensing Deal Worth $600 Million with UAE Pharma Company - 코메디닷컴","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNS0RRVE5UazVING00RUc4bXE1eERFY3Y1bDZ6ajJfOFRzRnpwc2FuSG9wSWxYMXdzeThHbjhVaVVqOG9CMGt2cmZEdHk4SVBEeV9NV3BYYkVJVFJuMkFDOUpuVmt6WTdpUFBBVHpOeW91M3psTGhnV1hoVTBlSzVKY0tlRFFtWjkzcGx6TUNtc3c1UDAwVDFvNWtkamF6YWIxN1ZhcnRR?oc=5","date":"2025-06-10","type":"deal","source":"BioWorld News","summary":"Aribio fortifies Arcera alliance with $600M AR-1001 supply deal - BioWorld News","headline":"Aribio fortifies Arcera alliance with $600M AR-1001 supply deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxNdTlUVV9UQ0M2bmowemt4UVFrZHlSbzRpMlZ0dnFfNVdOaTEwb1lPNnNiaHFYZFV5TVBJclBuT2dnZU9OeXhqV2Vtc2NabVpSZXY2bXdNblFvR2t2Sl93MGF0bkgxbzJCblZhWUxuckZXdTlxZExlQ2RiRGtHakNpU3dqNG5uaG4yNkUwYVVDM3hxVW1fbDdGdUdSRGxGanl3aHd1cmE2cWJuaUhOSlBtc242M2VnWnpFRm9EdGJLeGJNWk5EbWRWb19yWW9ob2g5T2dFRjNINlNRYm1fTG41dmxIWU9WQkxhUlJpVGZXcjY3enRJR1liTVIzcXZjZFVSTFVVbWp2alhuOXVLc1oyZ1dQajZlRWptMTVOTHdyRE02YWV1RWNNWXV3c1pxWjVmMXRjM3pubmthc0p5ZEVvMkpkOWZaZlB3TlE?oc=5","date":"2025-04-29","type":"trial","source":"GlobeNewswire","summary":"Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Phenylketonuria Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPMzBDcWc3MnZSY1NpanZnUVhGYUtoem9MeV9WZUlwSkVhY0ZvTm9BZWt3NmliMVFicEM2MU1peTg1YWVSSzNUZ1h4RGh2dHEtd2Z4OE1kT2tySlVVVjE2OXZ1WlNnT25SRVhQVXo3ZzB2aE1NUmhVUHlJeVBiY0FpVkFxTzQ2dWpwQVppNkZxeWRJNHVtNm5JTmJwUmhKNXhadjh0cXFnaVoyWWFHVU56cUR4bVhCckdHUjBCS2NZTHhvb0VkSmVfbmpaTzdqY3FBdWFuOQ?oc=5","date":"2024-04-30","type":"regulatory","source":"BioPharma APAC","summary":"AriBio Secures EMA Approval for Pivotal POLARIS-AD Alzheimer's Trial, Aligning with FDA and MHRA - BioPharma APAC","headline":"AriBio Secures EMA Approval for Pivotal POLARIS-AD Alzheimer's Trial, Aligning with FDA and MHRA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNdTlxWi1lNVZjUzNEdllULXVHVXpsSEJQSjZHSDdDMlVTR1JZQm13TnctVURYcmR4OHN3Y3dMLWgybHg3N245cDA1YzNfNnZoZW5fWlpDWUh2VlZPM19MZElsRXNzbG1KUWptY0FoS0l1U3dvVUV3UmxEZXhmQ2syMW1LOTVJTURDRXd1M3ZSSk83dVB4M2t0a3ZxNDVDNm0wN0VEWGNnSFR3d1p3VS1DYzZVX2JNM2ZzZ3ZzbjhBNy1YemdHbU1nZ001akV2RWE1REVuNUVrRHh4WERJU2lYckVCeVoyMGpCc0ctcEgyV0hOQW16UU83eg?oc=5","date":"2024-03-24","type":"deal","source":"Business Wire","summary":"AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD - Business Wire","headline":"AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1OMl9TUzhuc1djcW1DUVlTQ19FUFpSa3NLT1BHeEctcTBLWkNNaFE5NGlGZGVCamhWU0hIZTlERmdUSmhMMjlLUlMyQnEtekJGbDJmMmszQVBGWGdpSWFPR2xnZFBTRjAzQW1scndn?oc=5","date":"2023-09-12","type":"deal","source":"KED Global","summary":"Wellmarker Bio signs worth of $528 mn tech transfer deal - KED Global","headline":"Wellmarker Bio signs worth of $528 mn tech transfer deal","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}